TreatmentUpdate 76. 9(2): 3-4; March, 1997
Sean Hosein
Study details
One small American study enrolled 30 male subjects who had an average of 79 CD4+ cells. About 90% had used AZT or related drugs for more than 3 years before entering this trial. All subjects had a viral load greater than 5,000 copies. They received the following:
* ritonavir 600 mg twice daily
* saquinavir 400 mg twice daily
as well as two ?nukes? (nucleoside analogues ? AZT and related drugs):
* AZT 600 mg/day and 3TC 300 mg/day
* d4T 80 mg/day and ddI 200 mg/day
* d4T 80 mg/day and 3TC 300 mg/day
Half the subjects received d4T and 3TC.
Results
By the 4th month of the study, the following occurred:
* average CD4+ cell count rose to 101 cells
* average amount of HIV fell to 1/10th its pre-study level
Results ? toxicity
Roughly 63% of subjects had side effects, the most common being:
* nausea
* tiredness
* intestinal discomfort.
Two subjects had their dose of ritonavir reduced to 400 mg twice daily because of its toxicity.
REFERENCES:
1. Barbour CO. Efficacy and safety of quadruple combination therapy in treatment-experienced HIV/AIDS patients. Poster 245.
970320
CATE7603
Copyright © 1997 - TreatmentUpdate. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, The Canadian AIDS Treatment Information Exchange, 555 Richmond St. West, Suite 505, Box 1104, Toronto, ON, M5V 3B1 • Phone: 416-203-7122 • Toll Free: 1-800-263-1638 • Fax: 416-203-8284 http://www.catie.ca
Disclaimer: The editors have taken all such care as they consider reasonable in preparing this database, but they cannot be held responsible for any inaccuracies or mis-statements of fact contained herein. Inclusion in this database of any information on any treatment, therapy, or clinical trial in no way represents an endorsement of that treatment, therapy, or trial by ÆGiS or any of its sponsors. This data should always be used in conjunction with professional medical advice.